Objective:
To analyze the current state of Europe's antibiotic supply chain and propose structural reforms to ensure the sustainability and availability of essential off-patent antibiotics.
Approach:
- Economic Analysis: The report examines the economic sustainability of off-patent antibiotics in light of declining prices and rising production costs.
- Policy Recommendations: It outlines interlinked policy goals and practical recommendations to stabilize the antibiotic supply chain.
Key Findings:
- Prices for widely used off-patent antibiotics fell by over 10% from 2020 to 2024, while production costs surged by more than 30%.
- A diverse supplier base is essential to prevent monopolistic fragility and ensure effective responses to demand fluctuations.
- Financial incentives must align with antimicrobial stewardship to maintain the availability of essential drugs.
Interpretation:
The report calls for structural reform in antibiotic supply policies to ensure long-term sustainability and access to essential medicines.
Limitations:
- The report does not provide specific case studies beyond Sweden's pilot revenue guarantee model.
- It may not address all potential market dynamics affecting antibiotic supply.
Conclusion:
Sustaining access to antibiotics requires a recalibration of Europe’s pharmaceutical policy framework, focusing on reliability and quality of supply.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
